Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research

Archives of Toxicology

Volumn 91, Issue 8, 2017, Pages 2763-2780

  Pelkonen, Olavi ^a   Terron, Andrea ^b   Hernandez, Antonio F ^c   Menendez, Pablo ^d,e,f   Bennekou, Susanne Hougaard ^g   Angeli, Karine ^h   Fritsche, Ellen ^h   Leist, Marcel ^h   Mantovani, Alberto ^h   Price, Anna ^h   Viviani, Barbara ^h  

^a UNIVERSITY OF OULU   (Finland)

^b EUROPEAN FOOD SAFETY AUTHORITY   (Italy)

^c UNIVERSITY OF GRANADA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^f Autonomous University of Madrid Instituto de Investigación Hospital Universitario La Paz   (Spain)

^g The Danish Environmental Protection Agency EPA   (Denmark)

^h NONE

Author keywords

DNA topoisomerase II; Etoposide; Infant leukaemia; MLL fusion products; Risk assessment

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; GYRASE INHIBITOR; HISTONE LYSINE METHYLTRANSFERASE; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; PESTICIDE;

ACUTE LEUKEMIA; ADVERSE OUTCOME; CANCER GROWTH; CHILDHOOD LEUKEMIA; CHROMOSOME TRANSLOCATION; ENVIRONMENTAL EXPOSURE; EVIDENCE BASED PRACTICE; FETUS DEVELOPMENT; FUSION GENE; GENE REARRANGEMENT; GENETIC SUSCEPTIBILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFANT; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK ASSESSMENT; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE OUTCOME PATHWAY; ANIMAL; CHEMICALLY INDUCED; GENETICS; PROCEDURES;

ADVERSE OUTCOME PATHWAYS; ANIMALS; ENVIRONMENTAL EXPOSURE; ETOPOSIDE; GENE REARRANGEMENT; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; INFANT; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PESTICIDES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK ASSESSMENT; TOPOISOMERASE II INHIBITORS;

EID: 85019958919     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-017-1986-x     Document Type: Review

References (100)

1. Alexander FE, Patheal SL, Biondi A, Brandalise S, Cabrera ME, Chan LC, Chen Z, Cimino G, Cordoba JC, Gu LJ, Hussein H, Ishii E, Kamel AM, Labra S, Magalhaes IQ, Mizutani S, Petridou E, de Oliveira MP, Yuen P, Wiemels JL, Greaves MF (2001) Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res 61(6):2542–2546
2. Andersson AK, Ma J, Wang J. (2015) The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet 47(4):330–337. doi:10.1038/ng.3230
3. Azarova AM, Lin RK, Tsai YC, Liu LF, Lin CP, Lyu YL (2010) Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia. Biochem Biophys Res Commun 399(1):66–71. doi:10.1016/j.bbrc.2010.07.043
4. Ballabio E, Milne TA (2012) Molecular and epigenetic mechanisms of MLL in human leukemogenesis. Cancers (Basel). 4(3):904–944. doi:10.3390/cancers4030904
5. Ballabio E, Milne TA (2014) Epigenetic control of gene expression in leukemogenesis: cooperation between wild type MLL and MLL fusion proteins. Mol Cell Oncol. 1(2):e955330. doi:10.1080/23723548.2014.955330
6. Bandele OJ, Osheroff N (2007) Bioflavonoids as poisons of human topoisomerase II alpha and II beta. Biochemistry 46(20):6097–6108
7. Bandele OJ, Clawson SJ, Osheroff N (2008) Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement. Chem Res Toxicol 21:1253–1260
8. Bardini M, Woll PS, Corral L, Luc S, Wittmann L, Ma Z, Lo Nigro L, Basso G, Biondi A, Cazzaniga G, Jacobsen SE (2015) Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia 29(1):38–50. doi:10.1038/leu.2014.154
9. Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O’Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O’Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M (2015) MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Rep. 13(12):2715–2727. doi:10.1016/j.celrep.2015.12.003
10. Blanco JG, Edick MJ, Relling MV (2004) Etoposide induces chimeric Mll gene fusions. FASEB J 18(1):173–175. doi:10.1096/fj.03-0638fje
11. Borkhardt A, Wilda M, Fuchs U, Gortner L, Reiss I (2003) Congenital leukaemia after heavy abuse of permethrin during pregnancy. Arch Dis Child Fetal Neonatal Ed 88(5):F436–F437
12. Breese EH, Buechele C, Dawson C, Cleary ML, Porteus MH (2015) Use of genome engineering to create patient specific MLL translocations in primary human hematopoietic stem and progenitor cells. PLoS ONE 10(9):e0136644. doi:10.1371/journal.pone.0136644
13. Buechele C, Breese EH, Schneidawind D, Lin CH, Jeong J, Duque-Afonso J, Wong SH, Smith KS, Negrin RS, Porteus M, Cleary ML (2015) MLL leukemia induction by genome editing of human CD34 + hematopoietic cells. Blood 126(14):1683–1694. doi:10.1182/blood-2015-05-646398
14. Bueno C, Catalina P, Melen GJ, Montes R, Sanchez L, Ligero G, Garcia-Perez JL, Menendez P (2009) Etoposide induces MLL rearrangements and other chromosomal abnormalities in human embryonic stem cells. Carcinogenesis 30(9):1628–1637. doi:10.1093/carcin/bgp169
15. Bursen A, Schwabe K, Ruster B et al (2010) The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood 115(17):3570–3579
16. Castano J, Herrero AB, Bursen A, Gonzalez F, Marschalek R, Gutierrez NC, Menendez P (2016) Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair. Oncotarget. doi:10.18632/oncotarget.8938
17. Chen C-W, Armstrong SA (2015) Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol 43:673–684
18. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH (2006) A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood 108(2):669–677. doi:10.1182/blood-2005-08-3498
19. Choi J, Polcher A, Joas A (2016) Systematic literature review on Parkinson’s disease and Childhood Leukaemia and mode of actions for pesticides. EFSA supporting publication: EN-955, 256 pp
20. Cowell IG, Austin CA (2012) Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents. Int J Environ Res Public Health 9(12):2075–2091
21. de la Chica RA, Mediano C, Salido M, Espinet B, Manresa JM, Solé F (2011) Increased MLL gene rearrangements in amniocytes from fetuses of mothers who smoke. Leuk Res 35(8):1066–1069. doi:10.1016/j.leukres.2011.04.010
22. Dobbins SE, Sherborne AL, Ma YP, Bardini M, Biondi A, Cazzaniga G, Lloyd A, Chubb D, Greaves MF, Houlston RS (2013) The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia. Genes Chromosomes Cancer 52(10):954–960. doi:10.1002/gcc.22090 Epub 2013 Jul 26
23. Driessen EM, van Roon EH, Spijkers-Hagelstein JA, Schneider P, de Lorenzo P, Valsecchi MG, Pieters R, Stam RW (2013) Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica 98(6):937–944. doi:10.3324/haematol.2012.067983
24. Edwards SW, Tan YM, Villeneuve DL, Meek ME, McQueen CA (2016) Adverse outcome pathways-organizing toxicological information to improve decision making. J Pharmacol Exp Ther 356(1):170–181
25. Emerenciano M, Barbosa TC, de Almeida Lopes B, Meyer C, Marschalek R, Pombo-de-Oliveira MS (2015) Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia. Br J Haematol 170(2):268–271. doi:10.1111/bjh.13279
26. Ernest P, Wang J, Korsmeyer SJ (2002) The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol 9:282–287
27. Ernest P, Fisher JK, Avery W, Sade S, Foy D, Korsmeyer SJ (2004) Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev Cell 6:437–443
28. Ezoe S (2012) Secondary leukemia associated with the anti-cancer agent, etoposide, a topoisomerase II inhibitor. Int J Environ Res Public Health. 9(7):2444–2453. doi:10.3390/ijerph9072444
29. Farooq Z, Banday S, Pandita TK, Altaf M (2016) The many faces of histone H3K79 methylation. Mutat Res, Rev Mutat Res 768:46–52
30. Felix CA, Kolaris CP, Osheroff N (2006) Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst). 5(9–10):1093–1108
31. Ferreira JD, Couto AC, Pombo-de-Oliveira MS, Koifman S, Brazilian Collaborative Study Group of Infant Acute Leukemia (2013) In utero pesticide exposure and leukemia in Brazilian children < 2 years of age. Environ Health Perspect 121(2):269–275. doi:10.1289/ehp.1103942
32. Ford AM, Ridge SA, Cabrera ME, Mahmoud H, Steel CM, Chan LC et al (1993) In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature 363(6427):358–360. doi:10.1038/363358a0
33. Fortune JM, Osheroff N (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage. J Biol Chem 273(28):17643–17650
34. Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB et al (1997) Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA 94(25):13950–13954
35. Godfrey L, Kerry J, Thorne R, Repapi E, Davies JO, Tapia M, Ballabio E, Hughes JR, Geng H, Konopleva M, Milne TA (2017) MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation. Exp Hematol 47:64–75. doi:10.1016/j.exphem.2016.11.003
36. Gole B, Wiesmüller L (2015) Leukemogenic rearrangements at the mixed lineage leukemia gene (MLL)-multiple rather than a single mechanism. Front Cell Dev Biol. 25(3):41. doi:10.3389/fcell.2015.00041
37. Gordon ON, Luis PB, Ashley RE, Osheroff N, Schneider C (2015) Oxidative transformation of demethoxy- and bisdemethoxycurcumin: products, mechanism of formation, and poisoning of human topoisomerase IIβ. Chem Res Toxicol 28(5):989–996. doi:10.1021/acs.chemrestox.5b00009
38. Greaves M (2002) Childhood leukaemia. BMJ 324:283–287
39. Greaves M (2015) When one mutation is all it takes. Cancer Cell 27(4):433–434
40. Hernández AF, Menéndez P (2016) Linking pesticide exposure with pediatric leukemia: potential underlying mechanisms. Int J Mol Sci 17:461
41. Hess JL, Yu BD, Li B, Hanson RD, Korsmeyer SJ (1997) Defect in yolk sac hematopoiesis in mll-null embryos. Blood 90:1799–1806
42. Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 73:1541–1552
43. Ishii E, Eguchi M, Eguchi-Ishimae M, Yoshida N, Oda M, Zaitsu M et al (2002) In vitro cleavage of the MLL gene by topoisomerase II inhibitor (etoposide) in normal cord and peripheral blood mononuclear cells. Int J Hematol 76(1):74–79
44. Jansen MW, Corral L, van der Velden VH, Panzer-Grumayer R, Schrappe M, Schrauder A et al (2007) Immunobiological diversity in infant acute lymphoblastic leukemiais related to the occurence and type of MLL rearrangment. Leukemia 21(4):633–641
45. Joannides M, Grimwade D (2010) Molecular biology of therapy-related leukaemias. Clin Transl Oncol 12(1):8–14. doi:10.1007/s12094-010-0460-5
46. Joannides M, Mays AN, Mistry AR, Hasan SK, Reiter A, Wiemels JL, Felix CA, Coco FL, Osheroff N, Solomon E, Grimwade D (2011) Molecular pathogenesis of secondary acute promyelocytic leukemia. Mediterr J Hematol Infect Dis 3(1):e2011045. doi:10.4084/MJHID.2011.045
47. Kerry J, Godfrey L, Repapi E, Tapia M, Blackledge NP, Ma H, Ballabio E, O’Byrne S, Ponthan F, Heidenreich O, Roy A, Roberts I, Konopleva M, Klose RJ, Geng H, Milne TA (2017) MLL-AF4 spreading identifies binding sites that are distinct from super-enhancers and that govern sensitivity to DOT1L inhibition in leukemia. Cell Rep. 18(2):482–495. doi:10.1016/j.celrep.2016.12.054
48. Ketron AC, Osheroff N (2014) Phytochemicals as anticancer and chemopreventive topoisomerase II poisons. Phytochem Rev 13(1):19–35
49. Ketron AC, Gordon ON, Schneider C, Osheroff N (2013) Oxidative metabolites of curcumin poison human type II topoisomerases. Biochemistry 52:221–227
50. Krivtsov AV, Armstrong SA (2007) MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 7(11):823–833
51. Krivtsov AV, Feng Z, Lemieux ME et al (2008) H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14(5):355–368
52. Lanoue L, Green KK, Kwik-Uribe C, Keen CL (2010) Dietary factors and the risk for acute infant leukemia: evaluating the effects of cocoa-derived flavanols on DNA topoisomerase activity. Exp Biol Med (Maywood). 235(1):77–89. doi:10.1258/ebm.2009.009184
53. Leone G, Pagano L, Ben-Yehuda D, Voso MT (2007) Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 92(10):1389–1398
54. Li Z, Sun B, Clewell RA, Adeleye Y, Andersen ME, Zhang Q (2014) Dose–response modeling of etoposide-induced DNA damage response. Toxicol Sci 137(2):371–384. doi:10.1093/toxsci/kft259
55. Libura J, Slater DJ, Felix CA, Richardson C (2005) Therapy-related acute myeloid leukemia-like MLL rearrangements are induced by etoposide in primary human CD34 + cells and remain stable after clonal expansion. Blood 105(5):2124–2131. doi:10.1182/blood-2004-07-2683
56. Libura J, Ward M, Solecka J, Richardson C (2008) Etoposide-initiated MLL rearrangements detected at high frequency in human primitive hematopoietic stem cells with in vitro and in vivo long-term repopulating potential. Eur J Haematol 81(3):185–195. doi:10.1111/j.1600-0609.2008.01103.x
57. Lin RK, Zhou N, Lyu YL, Tsai YC, Lu CH, Kerrigan J, Chen YT, Guan Z, Hsieh TS, Liu LF (2011) Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα. J Biol Chem 286:33591–33600
58. Lin S, Luo RT, Ptasinska A, Kerry J, Assi SA, Wunderlich M, Imamura T, Kaberlein JJ, Rayes A, Althoff MJ, Anastasi J, O’Brien MM, Meetei AR, Milne TA, Bonifer C, Mulloy JC, Thirman MJ (2016) Instructive role of MLL-fusion proteins revealed by a model of t(4;11) Pro-B acute lymphoblastic leukemia. Cancer Cell 30(5):737–749. doi:10.1016/j.ccell.2016.10.008
59. Lopez-Lazaro M, Willmore E, Austin CA (2010) The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells. Mutat Res 696(1):41–47. doi:10.1016/j.mrgentox.2009.12.010
60. Lu C, Liu X, Liu C, Wang J, Li C, Liu Q, Li Y, Li S, Sun S, Yan J, Shao J (2015) Chlorpyrifos induces MLL tra nslocations through caspase 3-dependent genomic instability and topoisomerase II inhibition in human fetal liver hematopoietic stem cells. Toxicol Sci 147(2):588–606. doi:10.1093/toxsci/kfv153
61. Manara E, Baron E, Tregnago C, Aveic S, Bisio V, Bresolin S, Masetti R, Locatelli F, Basso G, Pigazzi M (2014) MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia. Blood 124(2):263–272. doi:10.1182/blood-2013-09-525741
62. Marschalek R (2010) Mechanisms of leukemogenesis by MLL fusion proteins. Brit J Haematol 2010(152):141–154. doi:10.1111/j.1365-2141.08459.x
63. McClendon AK, Osheroff N (2007) DNA topoisomerase II, genotoxicity and cancer. Mutation Res 623(1–2):83–97
64. McKerrell T, Moreno T, Ponstingl H, Bolli N, Dias JM, Tischler G, Colonna V, Manasse B, Bench A, Bloxham D, Herman B, Fletcher D, Park N, Quail MA, Manes N, Hodkinson C, Baxter J, Sierra J, Foukaneli T, Warren AJ, Chi J, Costeas P, Rad R, Huntly B, Grove C, Ning Z, Tyler-Smith C, Varela I, Scott M, Nomdedeu J, Mustonen V, Vassiliou GS (2016) Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies. Blood 128(1):e1–e9. doi:10.1182/blood-2015-11-683334
65. Menendez P, Catalina P, Rodriguez R, Melen GJ, Bueno C, Arriero M, Garcia-Sanchez F, Lassaletta A, Garcia-Sanz R, Garcia-Castro J (2009) Bone marrow mesenchymal stem cells from infants with MLL-AF4 + acute leukemia harbor and express the MLL-AF4 fusion gene. J Exp Med 206(13):3131–3141. doi:10.1084/jem.20091050
66. Metzler M, Forster A, Pannell R et al (2006) A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene 25(22):3093–3103
67. Meyer C, Hofmann J, Burmeister T et al (2013) The MLL recombinome of acute leukemias in 2013. Leukemia 27(11):2165–2176
68. Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Ades L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, Cross NC, Chomienne C, Solomon E, Fenaux P, Grimwade D (2005) DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 352(15):1529–1538
69. Moneypenny CG, Shao J, Song Y, Gallagher EP (2006) MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells. Carcinogenesis 27(4):874–881. doi:10.1093/carcin/bgi322 (Epub 2005/12/27)
70. Montecucco A, Zanetta F, Biamonti G (2015) Molecular mechanisms of etoposide. EXCLI J. 19(14):95–108. doi:10.17179/excli2015-561
71. Munoz-Lopez A, Romero-Moya D, Prieto C, Ramos-Meji-a V, Agraz-Doblas A, Varela I, Buschbeck M, Palau A, Carvajal-Vergara X, Giorgetti A, Ford A, Lako M, Granada I, Rodri-guez-Perales S, Torres-Rui-z R, Stam RW, Fuster JL, Fraga MF, Nakanishi M, Cazzaniga G, Bardini M, Cobo I, Bayon GF, Fernandez AF, Bueno C, Menendez P (2016) Development refractoriness of MLL-rearranged human B cell acute leukemias to reprogramming into pluripotency. Stem Cell Rep 7(4):602–618. doi:10.1016/j.stemcr.2016.08.013
72. Nanya M, Sato M, Tanimoto K, Tozuka M, Mizutani S, Takagi M (2015) Dysregulation of the DNA damage response and KMT2A rearrangement in fetal liver hematopoietic cells. PLoS ONE 10(12):e0144540. doi:10.1371/journal.pone.0144540
73. Niemeyer CM (2014) RAS diseases in children. Haematologica 99(11):1653–1662
74. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338–350
75. Ntzani EE, Chondrogiorgi M, Ntritsos G, Evangelou E and Tzoulaki I (2013) Literature review on epidemiological studies linking exposure to pesticides and health effects. EFSA supporting publication 2013: EN-497, 159 pp
76. Ockleford C, Adriaanse P, Berny P, Brock T, Duquesne S, Grilli S, Hernandez-Jerez AF, Bennekou SH, Klein M, Kuhl T, Laskowski R, Machera K, Pelkonen O, Pieper S, Smith R, Stemmer M, Sundh I, Teodorovic I, Tiktak A, Topping CJ, Wolterink G, Angeli K, Fritsche E, Hernandez-Jerez AF, Leist M, Mantovani A, Menendez P, Pelkonen O, Price A, Viviani B, Chiusolo A, Ruffo F, Terron A, Bennekou SH (2017) Scientific opinion on the investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson’s disease and childhood leukaemia. EFSA J 15(3):4691. doi:10.2903/j.efsa.2017.4691
77. OECD (2013) Guidance document on developing and assessing adverse outcome pathways. ENV/JM/MONO(2013) 6
78. Patlewitz G, Simon TW, Rowlands JC, Budinsky RA, Becker RA (2015) Proposing a scientific framework to help support the application of adverse outcome pathways for regulatory purposes. Regul Toxicol Pharmacol 7:463–477
79. Pendleton M, Lindsey RH Jr, Felix CA, Grimwade D, Osheroff N (2014) Topoisomerase II and leukemia. Ann N Y Acad Sci 1310:98–110. doi:10.1111/nyas.12358
80. Pombo-de-Oliveira MS, Koifman S, Brazilian Collaborative Study Group of Infant Acute Leukemia (2006) Infant acute leukemia and maternal exposures during pregnancy. Cancer Epidemiol Biomarkers Prev 15(12):2336–2341
81. Prelle C, Bursen A, Dingermann T, Marschalek R (2012) Secondary mutations in t(4;11) leukemia patients. Leukemia 27(6):1425–1427
82. Prieto C, Stam RW, Agraz-Doblas A, Ballerini P, Camos M, Castano J, Marschalek R, Bursen A, Varela I, Bueno C, Menendez P (2016) Activated KRAS cooperates with MLLAF4 to promote extramedullary engraftment and migration of cord blood CD34 + HSPC but is insufficient to initiate leukemia. Cancer Res 76(8):2478–2489. doi:10.1158/0008-5472
83. Relling MV, Yanishevski Y, Nemec J, Evans WE, Boyett JM, Behm FG, Pui CH (1998) Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12(3):346–352
84. Ross JA, Potter JD, Reaman GH, Pendergrass TW, Robison LL (1996) Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children’s Cancer Group. Cancer Causes Control 7(6):581–590
85. Sam TN, Kersey JH, Linabery AM, Johnson KJ, Heerema NA, Hilden JM et al (2012) MLL gene rearrangements in infant leukaemia vary with age at diagnosis and selected demographic factors: a Children’s Oncology Group (COG) study. Pediatr Blood Cancer 58(6):836–839
86. Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam RW, Marschalek R, Menendez P (2015) Revisiting the biology of infant t(4;11)/MLL-AF4 + B-cell acute lymphoblastic leukemia. Blood 126(25):2676–2685. doi:10.1182/blood-2015-09-667378
87. Schroeter A, Groh IA, Favero GD, Pignitter M, Schueller K, Somoza V, Marko D (2015) Inhibition of topoisomerase II by phase II metabolites of resveratrol in human colon cancer cells. Mol Nutr Food Res. doi:10.1002/mnfr.201500352
88. Spector LG, Xie Y, Robison LL, Heerema NA, Hilden JM, Lange B, Felix CA, Davies SM, Slavin J, Potter JD, Blair CK, Reaman GH, Ross JA (2005) Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children’s oncology group. Cancer Epidemiol Biomarkers Prev 14(3):651–655
89. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD (2000) Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci U S A. 97(9):4790–4795
90. Super HJ, McCabe NR, Thirman MJ et al (1993) Rearrangements of the MLL gene in therap-related acute myeloid leukaemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 82:3705–3711
91. Tamai H, Inokuchi K (2013) Establishment of MLL/AF4 transgenic mice with the phenotype of lymphoblastic leukemia or lymphoma. J Nippon Med Sch. 80(5):326–327
92. Tamai H, Miyake K, Takatori M, Miyake N, Yamaguchi H, Dan K, Shimada T, Inokuchi K (2011) Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia 25(5):888–891. doi:10.1038/leu.2011.15
93. Teitell MA, Pandolfi PP (2009) Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol 4:175–198
94. Thys RG, Lehman CE, Pierce LCT, Wang YH (2015) Environmental and chemotherapeutic agents induce breakage at genes involved in leukemia-causing gene rearrangements in human hematopoietic stem/progenitor cells. Mutat Res/Fundam Mol Mech Mutagenesis 779:86–95
95. Tollefsen KE, Scholz S, Cronin MT, Edwards SW, de Knecht J, Crofton K, Garcia-Reyero N, Hartung T, Worth A, Patlewitz G (2014) Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA). Regul Toxiciol Pharmacol 70:629–640
96. Udroiu I, Sgura A (2012) Genotoxicity sensitivity of the developing hematopoietic system. 2012. Mutat Res 767:1–7
97. van Doorn-Khosrovani SBVW, Janssen J, Maas LM, Godschalk RW, Nijhuis JG, van Schooten FJ (2007) Dietary flavonoids induce MLL translocations in primary human CD34 + cells. Carcinogenesis 28(8):1703–1709
98. Vanhees K, de Bock L, Godschalk RW, van Schooten FJ, van Doorn-Khosrovani SBVW (2011) Prenatal exposure to flavonoids: implication for cancer risk. Toxicol Sci 120(1):59–67. doi:10.1093/toxsci/kfq388
99. Vinken M (2013) The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312:158–165
100. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ (1998) MLL, a mammalian trithorax-group gene, functions as atrascriptional maintenance factor in morphogenesis. Proc Natl Acad Sci USA 95:10632–10636